Clinical Trials Logo

Relapse clinical trials

View clinical trials related to Relapse.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02661061 Terminated - Depression Clinical Trials

Ketamine for Relapse Prevention in Recurrent Depressive Disorder

KINDRED
Start date: December 2015
Phase: Phase 1
Study type: Interventional

Randomised, controlled, parallel-group, pilot clinical trial of ketamine vs. midazolam for depression relapse prevention in persons at high risk. The main purpose of the pilot study is to assess trial processes to help inform a future definitive trial.

NCT ID: NCT00907582 Terminated - Relapse Clinical Trials

ASCT for Relapsed APL After Molecular Remission

Start date: June 2009
Phase: Phase 2
Study type: Interventional

For relapsed acute promyelocytic leukemia after all-trans retinoic acid (ATRA) and arsenic treatment, remission can be achieved by chemotherapy with ATRA and/or arsenic and addition of mylotarg. Autologous hematopoietic cell transplantation using a polymerase chain reaction (PCR) negative graft is important treatment option to obtain sustainable remission. This study is to test the efficacy and the safety of conditioning regimen with idarubicin and busulfan for relapsed Acute Promyelocytic Leukemia (APL).

NCT ID: NCT00888810 Terminated - Cancer Clinical Trials

Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer

TOPO-LAPA
Start date: March 2008
Phase: Phase 2
Study type: Interventional

The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in patients who failed first line platinum-based chemotherapy within 12 months.

NCT ID: NCT00882193 Terminated - Chronic Hepatitis C Clinical Trials

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

Start date: May 1, 2009
Phase: Early Phase 1
Study type: Interventional

This is a non-randomized, open-label study examining the safety and efficacy of betaine in addition to standard anti-viral therapy in genotype 1 hepatitis C non-responders or relapsers to previous pegylated interferon plus ribavirin. Betaine (20 gm/day) in 2 divided doses will be added to Peginterferon alpha 2a (180 mcg) plus weight-based Ribavirin (1000 or 1200 mg/day, for body weight < or > 75 kg, respectively, for 48 weeks. Patients must be diagnosed with chronic hepatitis C, genotype I, and have undergone therapy for hepatitis C with pegylated interferon plus ribavirin. Subjects will be followed for safety, tolerability, hepatitis C viral response and the effect on interferon gene signaling in peripheral blood mononuclear cells during therapy.